Transcription of Public Assessment Report Decentralised Procedure …
{{id}} {{{paragraph}}}
Example: tourism industry
Public Assessment Report Decentralised Procedure …
Public Assessment Report Decentralised Procedure MOLITA 200MG/25MG MODIFIED-RELEASE CAPSULES, HARD DIPYRIDAMOLE/ acetylsalicylic ACID 200MG/25MG MODIFIED-RELEASE CAPSULES, HARD Procedure No: UK/H/4642/001/DC UK/H/5032/001/DC UK Licence No: PL 08553/0466 PL 08553/0473 Dr. Reddy s Laboratories (UK) Limited PAR Dipyridamole/ acetylsalicylic Acid 200mg/25mg modified-release caps UK/H/4642&5032/001/DC 2 LAY SUMMARY On 16 August 2012, Germany and the UK agreed to grant Marketing Authorisations to Dr Reddy s Laboratories (UK) Limited for the medicinal products Molita 200mg/25mg modified-release capsules, hard and Dipyridamole/ acetylsalicylic Acid 200mg/25mg modified-release capsules, hard (PL 08553/0466 UK/H/4642 & 5032/001/DC). The licences were granted via the Decentralised Procedure (DCP), with the UK as Reference Member State (RMS). After the national phase, Marketing Authorisations were granted in the UK on 9 October 2012.
Public Assessment Report Decentralised Procedure MOLITA 200MG/25MG MODIFIED-RELEASE CAPSULES, HARD DIPYRIDAMOLE/ACETYLSALICYLIC ACID 200MG/25MG MODIFIED-RELEASE CAPSULES,
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: